Company registration number 02337313 (England and Wales)
BIOPHARMA PROCESS SYSTEMS LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
BIOPHARMA PROCESS SYSTEMS LIMITED
COMPANY INFORMATION
Directors
A E Cowen
R J Lowe
M R Richards
K Ward
P Conway
R Castangia
Secretary
M R Richards
Company number
02337313
Registered office
Biopharma House
Winnall Valley Road
Winnall
Winchester
Hampshire
United Kingdom
SO23 0LD
Auditor
Azets Audit Services
2nd Floor
Regis House
45 King William Street
London
EC4R 9AN
Business address
Biopharma House
Winnall Valley Road
Winnall
Winchester
Hampshire
United Kingdom
SO23 0LD
BIOPHARMA PROCESS SYSTEMS LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2
Directors' responsibilities statement
3
Independent auditor's report
4 - 6
Profit and loss account
7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Statement of cash flows
11
Notes to the financial statements
12 - 27
BIOPHARMA PROCESS SYSTEMS LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -
The directors present the strategic report for the year ended 31 December 2024.
Review of the business
During the year the company has seen a decrease in its turnover to £10,088,840 (2023: £14,155,445) and a reduction in gross profit to £2,207,208 (2023: £3,167,284). This reflects a defensive attitude within the life sciences industry where investment in products and plant have been deferred or cancelled as a result of political, financial and sector uncertainty. For UK based organisations, the budget of October ’24 with several adverse tax consequences looks unlikely to spark the growth that was promised and the wider economic future for both the UK and the US remains uncertain with the topspin of a tariff war. Against this backdrop the company has taken steps to maintain its critical mass whilst carefully managing costs.
Principal risks and uncertainties
The company's financial instruments at the balance sheet date comprised of bank loans, HP loans and cash and liquid resources. In addition, the company has other financial instruments such as trade debtors and trade creditors that arise directly from its operations. The main purpose of these financial instruments is to provide working capital for the company’s activities.
The main risks from the company’s financial instruments are interest rate risk, liquidity risk and foreign currency risk. In common with businesses of a similar size, these risks are managed by the board, who set the policies and circumstances for the use of financial instruments and with are monitored and reviewed on an ongoing basis.
Interest rate risk
The company's loan comprise both fixed and floating rate liabilities. Any exposure to interest rate fluctuations is managed in order that the company's operations are financed through retained profits.
Liquidity and cash flow risk
Liquidity risk is managed through forecasting the future cash flow requirements of the business and maintaining sufficient cash, overdraft and loan facilities are in place.
Exchange rate risk
A significant number of transactions are in foreign currency so any movement on the exchange rate can have an effect on the company. To reduce the risk, the group that this company is part of has a presence in the US and Europe, as well as using foreign forward contracts on significant purchases.
A E Cowen
Director
4 July 2025
BIOPHARMA PROCESS SYSTEMS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
The directors present their annual report and financial statements for the year ended 31 December 2024.
Principal activities
The principal activity of the company continued to be that of suppliers of specialist equipment to the process industries.
Results and dividends
The results for the year are set out on page 7.
No ordinary dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
A E Cowen
R J Lowe
M R Richards
K Ward
P Conway
R Castangia
Auditor
The auditors, Azets Audit Services, will be proposed for re-appointment at the forthcoming Annual General Meeting.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
On behalf of the board
A E Cowen
Director
4 July 2025
BIOPHARMA PROCESS SYSTEMS LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
BIOPHARMA PROCESS SYSTEMS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF BIOPHARMA PROCESS SYSTEMS LIMITED
- 4 -
Opinion
We have audited the financial statements of Biopharma Process Systems Limited (the 'company') for the year ended 31 December 2024 which comprise the profit and loss account, the statement of comprehensive income, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
BIOPHARMA PROCESS SYSTEMS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF BIOPHARMA PROCESS SYSTEMS LIMITED
- 5 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
BIOPHARMA PROCESS SYSTEMS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF BIOPHARMA PROCESS SYSTEMS LIMITED
- 6 -
Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.
We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework. Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.
In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:
Enquiry of management and those charged with governance around actual and potential litigation and claims as well as actual, suspected and alleged fraud;
Reviewing minutes of meetings of those charged with governance;
Assessing the extent of compliance with the laws and regulations considered to have a direct material effect on the financial statements or the operations of the company through enquiry and inspection;
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;
Performing audit work over the risk of management bias and override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for indicators of potential bias.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Julian Golding
Senior Statutory Auditor
For and on behalf of Azets Audit Services
15 July 2025
Chartered Accountants
Statutory Auditor
2nd Floor
Regis House
45 King William Street
London
EC4R 9AN
BIOPHARMA PROCESS SYSTEMS LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2024
2023
Notes
£
£
Turnover
3
10,088,840
14,155,445
Cost of sales
(7,881,632)
(10,988,161)
Gross profit
2,207,208
3,167,284
Administrative expenses
(2,431,301)
(2,133,410)
Other operating income
270,083
374,837
Operating profit
4
45,990
1,408,711
Interest receivable and similar income
7
136,742
28,939
Interest payable and similar expenses
8
(29,220)
(35,216)
Profit before taxation
153,512
1,402,434
Tax on profit
9
(11,807)
(295,527)
Profit for the financial year
141,705
1,106,907
The profit and loss account has been prepared on the basis that all operations are continuing operations.
BIOPHARMA PROCESS SYSTEMS LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
£
£
Profit for the year
141,705
1,106,907
Other comprehensive income
-
-
Total comprehensive income for the year
141,705
1,106,907
BIOPHARMA PROCESS SYSTEMS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Goodwill
11
31,741
40,021
Tangible assets
12
3,231,638
2,808,893
Investments
13
122,216
57,384
3,385,595
2,906,298
Current assets
Stocks
15
2,039,370
1,058,033
Debtors
16
4,122,101
3,021,519
Cash at bank and in hand
4,232,170
5,120,662
10,393,641
9,200,214
Creditors: amounts falling due within one year
17
(3,701,457)
(2,290,253)
Net current assets
6,692,184
6,909,961
Total assets less current liabilities
10,077,779
9,816,259
Creditors: amounts falling due after more than one year
18
(344,218)
(312,575)
Provisions for liabilities
Deferred tax liability
21
343,109
254,937
(343,109)
(254,937)
Net assets
9,390,452
9,248,747
Capital and reserves
Called up share capital
23
10,426
10,426
Share premium account
14,484
14,484
Profit and loss reserves
9,365,542
9,223,837
Total equity
9,390,452
9,248,747
The financial statements were approved by the board of directors and authorised for issue on 4 July 2025 and are signed on its behalf by:
A E Cowen
Director
Company Registration No. 02337313
BIOPHARMA PROCESS SYSTEMS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2023
10,426
14,484
8,934,656
8,959,566
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
-
1,106,907
1,106,907
Dividends
10
-
-
(817,726)
(817,726)
Balance at 31 December 2023
10,426
14,484
9,223,837
9,248,747
Year ended 31 December 2024:
Profit and total comprehensive income for the year
-
-
141,705
141,705
Balance at 31 December 2024
10,426
14,484
9,365,542
9,390,452
BIOPHARMA PROCESS SYSTEMS LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
26
78,265
1,744,889
Interest paid
(29,220)
(35,216)
Income taxes paid
(219,687)
(175,000)
Net cash (outflow)/inflow from operating activities
(170,642)
1,534,673
Investing activities
Purchase of tangible fixed assets
(719,319)
(1,236,056)
Proceeds on disposal of tangible fixed assets
39,004
9,750
Purchase of investments
(64,832)
Interest received
136,742
28,939
Net cash used in investing activities
(608,405)
(1,197,367)
Financing activities
Repayment of bank loans
(44,422)
(39,815)
Payment of finance leases obligations
(65,023)
(109,646)
Dividends paid
(817,726)
Net cash used in financing activities
(109,445)
(967,187)
Net decrease in cash and cash equivalents
(888,492)
(629,881)
Cash and cash equivalents at beginning of year
5,120,662
5,750,543
Cash and cash equivalents at end of year
4,232,170
5,120,662
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
1
Accounting policies
Company information
Biopharma Process Systems Limited is a private company limited by shares incorporated in England and Wales. The registered office is Biopharma House, Winnall Valley Road, Winnall, Winchester, Hampshire, United Kingdom, SO23 0LD.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.
1.4
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is ten years.
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 13 -
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold land and buildings
Over the lease term
Fixtures and fittings
Over 10 years
Motor vehicles
Over 4 years
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.6
Fixed asset investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
1.7
Impairment of fixed assets
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.8
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Work in progress is valued at the lower of cost and net realisable value.
1.9
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 14 -
1.10
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 15 -
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.11
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.12
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.13
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.14
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.15
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 17 -
2
Judgements and key sources of estimation uncertainty
The preparation of financial statements requires management to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on a continuing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
The key judgements and sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described below.
(i) Impairment of debtors
The Company makes an estimate of the recoverable value of its debtors, including inter-company and other debtors. When assessing impairment of debtors, management considers factors including any history of non-payment by the counter-party or any other factors which indicate that they may not be able to settle their obligation to the company in full.
(ii) Impairment of stock
The Company makes an estimate of the stock obsolescence. When assessing the impairment of stock, management considers factors including future selling price of stock and expected demand and best before dates of goods for resale.
(iii) Useful economic lives of tangible assets
The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement future investments, economic utilisation and the physical condition of the assets.
3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by class of business
Pharmaceutical capital goods sales
3,141,701
4,788,818
Airflow capital goods sales
2,385,417
4,163,359
Pharmaceutical equipment service and parts
2,089,402
2,012,564
Technology products and services
2,472,320
3,190,704
10,088,840
14,155,445
2024
2023
£
£
Turnover analysed by geographical market
United Kingdom
6,937,802
11,234,329
Europe
1,989,154
1,912,255
United States
849,581
617,747
Asia
230,549
126,322
Rest of the world
81,754
264,792
10,088,840
14,155,445
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
3
Turnover and other revenue
(Continued)
- 18 -
2024
2023
£
£
Other revenue
Interest income
136,742
28,939
4
Operating profit
2024
2023
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses
17,079
6,584
Fees payable to the company's auditor for the audit of the company's financial statements
16,200
16,200
Depreciation of owned tangible fixed assets
268,118
242,906
Profit on disposal of tangible fixed assets
(10,548)
(9,750)
Amortisation of intangible assets
8,280
8,280
Operating lease charges
34,230
37,834
5
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Directors
2
2
Operations
55
46
Temps
9
12
Total
66
60
2024
2023
£
£
Wages and salaries
2,978,224
2,757,826
Social security costs
334,914
275,135
Pension costs
241,250
137,683
3,554,388
3,170,644
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 19 -
6
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
184,423
174,070
Company pension contributions to defined contribution schemes
22,939
16,182
207,362
190,252
7
Interest receivable and similar income
2024
2023
£
£
Interest income
Interest on bank deposits
90,230
23,906
Interest receivable from group companies
4,764
5,033
Other interest income
41,748
Total income
136,742
28,939
2024
2023
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
94,994
28,939
8
Interest payable and similar expenses
2024
2023
£
£
Interest on financial liabilities measured at amortised cost:
Interest on invoice finance arrangements
22,120
27,920
Other finance costs:
Interest on finance leases and hire purchase contracts
7,100
7,296
29,220
35,216
9
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
3,969
177,220
Adjustments in respect of prior periods
(80,334)
40,073
Total current tax
(76,365)
217,293
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
9
Taxation
2024
2023
£
£
(Continued)
- 20 -
Deferred tax
Origination and reversal of timing differences
88,172
78,234
Total tax charge
11,807
295,527
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
153,512
1,402,434
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.50%)
38,378
329,572
Tax effect of expenses that are not deductible in determining taxable profit
338
448
Tax effect of income not taxable in determining taxable profit
(2,637)
(2,291)
Change in unrecognised deferred tax assets
88,172
78,234
Effect of change in corporation tax rate
(90)
Group relief
(3,618)
(62,754)
Permanent capital allowances in excess of depreciation
(98,025)
(121,259)
Depreciation on assets not qualifying for tax allowances
66,343
57,083
Amortisation on assets not qualifying for tax allowances
2,070
1,946
Research and development tax credit
(25,525)
Other non-reversing timing differences
(2,759)
Under/(over) provided in prior years
(80,334)
40,073
Withholding tax adjustments
3,969
Taxation charge for the year
11,807
295,527
10
Dividends
2024
2023
£
£
Interim paid
817,726
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
11
Intangible fixed assets
Goodwill
£
Cost
At 1 January 2024 and 31 December 2024
82,801
Amortisation and impairment
At 1 January 2024
42,780
Amortisation charged for the year
8,280
At 31 December 2024
51,060
Carrying amount
At 31 December 2024
31,741
At 31 December 2023
40,021
12
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 January 2024
1,792,775
1,978,098
223,421
3,994,294
Additions
508,876
210,443
719,319
Disposals
(70,067)
(70,067)
At 31 December 2024
1,792,775
2,486,974
363,797
4,643,546
Depreciation and impairment
At 1 January 2024
132,716
896,754
155,931
1,185,401
Depreciation charged in the year
21,334
185,425
61,359
268,118
Eliminated in respect of disposals
(41,611)
(41,611)
At 31 December 2024
154,050
1,082,179
175,679
1,411,908
Carrying amount
At 31 December 2024
1,638,725
1,404,795
188,118
3,231,638
At 31 December 2023
1,660,059
1,081,344
67,490
2,808,893
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
12
Tangible fixed assets
(Continued)
- 22 -
The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.
2024
2023
£
£
Fixtures and fittings
181,338
208,580
Motor vehicles
190,927
61,426
372,265
270,006
13
Fixed asset investments
2024
2023
£
£
Investments in subsidiaries
14
122,216
57,384
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024
57,384
Additions
64,832
At 31 December 2024
122,216
Carrying amount
At 31 December 2024
122,216
At 31 December 2023
57,384
14
Subsidiaries
Details of the company's subsidiaries at 31 December 2024 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Biopharma Overseas Limited
Biopharma House, Winnall Valley Road, Winnall, Winchester SO23 0LD
Ordinary
100.00
-
Biopharma Technologies SAS
ZA Grange Neuve, 26 route de Bourgoin, 38790 Diemoz, France
Ordinary
83.00
-
Biopharma Technology LLC
40600 Ann Arbor Road East, Suite 201, Plymouth, MI 48170-4675
Ordinary
0
100.00
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 23 -
15
Stocks
2024
2023
£
£
Work in progress
1,169,287
253,827
Finished goods and goods for resale
870,083
804,206
2,039,370
1,058,033
16
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
2,422,529
2,166,675
Corporation tax recoverable
835,615
380,459
Amounts owed by group undertakings
541,007
168,822
Other debtors
1,793
12,829
Prepayments and accrued income
267,105
241,400
4,068,049
2,970,185
2024
2023
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
54,052
51,334
Total debtors
4,122,101
3,021,519
17
Creditors: amounts falling due within one year
2024
2023
Notes
£
£
Bank loans
19
47,224
46,237
Obligations under finance leases
20
67,276
62,485
Trade creditors
1,864,518
1,290,425
Amounts owed to group undertakings
12,065
Corporation tax
159,104
Other taxation and social security
347,894
229,219
Other creditors
36,844
Accruals and deferred income
1,178,597
649,822
3,701,457
2,290,253
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 24 -
18
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Bank loans and overdrafts
19
255,195
300,604
Obligations under finance leases
20
89,023
11,971
344,218
312,575
Amounts included above which fall due after five years are as follows:
Payable by instalments
48,149
85,106
19
Loans and overdrafts
2024
2023
£
£
Bank loans
302,419
346,841
Payable within one year
47,224
46,237
Payable after one year
255,195
300,604
The long-term loans are secured by fixed charges over the assets of the company.
The company has a debenture loan with Lloyds Commercial Finance of £54,067 (2023: £64,078). The loan is repayable over 12 years. The interest rate on the loan is LIBOR plus 2.95% per annum.
The company has a mortgage with Lloyds Bank of £248,351 (2023: £282,763). The loan is repayable over 10 years. The interest rate on the loan is LIBOR plus 2.95% per annum.
20
Finance lease obligations
2024
2023
Future minimum lease payments due under finance leases:
£
£
Within one year
77,565
65,023
In two to five years
93,193
12,498
170,758
77,521
Less: future finance charges
(14,459)
(3,065)
156,299
74,456
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 25 -
21
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
2024
2023
Balances:
£
£
Accelerated capital allowances
343,109
254,937
2024
Movements in the year:
£
Liability at 1 January 2024
254,937
Charge to profit or loss
88,172
Liability at 31 December 2024
343,109
22
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
241,250
137,683
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
23
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of £1 each
10,000
10,000
10,000
10,000
Ordinary B shares of £1 each
426
426
426
426
10,426
10,426
10,426
10,426
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 26 -
24
Operating lease commitments
Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2024
2023
£
£
Within one year
42,642
36,302
Between two and five years
146,940
136,200
In over five years
1,259,850
1,293,900
1,449,432
1,466,402
25
Ultimate controlling party
The parent company of Biopharma Process Systems Limited is PE487 Limited and its registered office is Biopharma House, Winnall Valley Road, Winchester, Hampshire, SO23 0LD.
PE487 Limited prepare consolidated accounts for the group, which are available at companies house.
26
Cash generated from operations
2024
2023
£
£
Profit for the year after tax
141,705
1,106,907
Adjustments for:
Taxation charged
11,807
295,527
Finance costs
29,220
35,216
Investment income
(136,742)
(28,939)
Gain on disposal of tangible fixed assets
(10,548)
(9,750)
Amortisation and impairment of intangible assets
8,280
8,280
Depreciation and impairment of tangible fixed assets
268,118
242,906
Movements in working capital:
(Increase)/decrease in stocks
(981,337)
162,845
(Increase)/decrease in debtors
(498,560)
1,151,705
Increase/(decrease) in creditors
1,246,322
(1,219,808)
Cash generated from operations
78,265
1,744,889
BIOPHARMA PROCESS SYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
27
Analysis of changes in net funds
1 January 2024
Cash flows
31 December 2024
£
£
£
Cash at bank and in hand
5,120,662
(888,492)
4,232,170
Borrowings excluding overdrafts
(346,841)
44,422
(302,419)
Obligations under finance leases
(74,456)
(81,843)
(156,299)
4,699,365
(925,913)
3,773,452
2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.100A E CowenR J LoweM R RichardsK WardP ConwayR CastangiaFirst Inital P A WilliamsFirst Inital K SmithM R Richards023373132024-01-012024-12-3102337313bus:CompanySecretary12024-01-012024-12-3102337313bus:Director12024-01-012024-12-3102337313bus:Director22024-01-012024-12-3102337313bus:Director32024-01-012024-12-3102337313bus:Director42024-01-012024-12-3102337313bus:Director52024-01-012024-12-3102337313bus:Director62024-01-012024-12-3102337313bus:Director72024-01-012024-12-3102337313bus:Director82024-01-012024-12-3102337313bus:RegisteredOffice2024-01-012024-12-31023373132024-12-31023373132023-01-012023-12-3102337313core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3102337313core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3102337313core:Goodwill2024-12-3102337313core:Goodwill2023-12-31023373132023-12-3102337313core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3102337313core:FurnitureFittings2024-12-3102337313core:MotorVehicles2024-12-3102337313core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3102337313core:FurnitureFittings2023-12-3102337313core:MotorVehicles2023-12-3102337313core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3102337313core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3102337313core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3102337313core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3102337313core:CurrentFinancialInstruments2024-12-3102337313core:CurrentFinancialInstruments2023-12-3102337313core:Non-currentFinancialInstruments2024-12-3102337313core:Non-currentFinancialInstruments2023-12-3102337313core:ShareCapital2024-12-3102337313core:ShareCapital2023-12-3102337313core:SharePremium2024-12-3102337313core:SharePremium2023-12-3102337313core:RetainedEarningsAccumulatedLosses2024-12-3102337313core:RetainedEarningsAccumulatedLosses2023-12-3102337313core:ShareCapital2022-12-3102337313core:SharePremium2022-12-3102337313core:RetainedEarningsAccumulatedLosses2022-12-3102337313core:ShareCapitalOrdinaryShares2024-12-3102337313core:ShareCapitalOrdinaryShares2023-12-310233731312024-01-012024-12-31023373132023-12-31023373132022-12-3102337313core:Goodwill2024-01-012024-12-3102337313core:LandBuildingscore:LongLeaseholdAssets2024-01-012024-12-3102337313core:FurnitureFittings2024-01-012024-12-3102337313core:MotorVehicles2024-01-012024-12-3102337313core:UKTax2024-01-012024-12-3102337313core:UKTax2023-01-012023-12-310233731312023-01-012023-12-310233731322024-01-012024-12-310233731322023-01-012023-12-310233731332024-01-012024-12-310233731332023-01-012023-12-310233731342024-01-012024-12-310233731342023-01-012023-12-3102337313core:Goodwill2023-12-3102337313core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3102337313core:FurnitureFittings2023-12-3102337313core:MotorVehicles2023-12-3102337313core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3102337313core:Subsidiary12024-01-012024-12-3102337313core:Subsidiary22024-01-012024-12-3102337313core:Subsidiary32024-01-012024-12-3102337313core:Subsidiary112024-01-012024-12-3102337313core:Subsidiary222024-01-012024-12-3102337313core:Subsidiary332024-01-012024-12-3102337313core:AfterOneYear2024-12-3102337313core:AfterOneYear2023-12-3102337313core:WithinOneYear2024-12-3102337313core:WithinOneYear2023-12-3102337313core:BetweenTwoFiveYears2024-12-3102337313core:BetweenTwoFiveYears2023-12-3102337313bus:OrdinaryShareClass12024-01-012024-12-3102337313bus:OrdinaryShareClass22024-01-012024-12-3102337313bus:OrdinaryShareClass12023-12-3102337313bus:OrdinaryShareClass22023-12-3102337313bus:AllOrdinaryShares2024-12-3102337313bus:AllOrdinaryShares2023-12-3102337313core:MoreThanFiveYears2024-12-3102337313core:MoreThanFiveYears2023-12-3102337313bus:PrivateLimitedCompanyLtd2024-01-012024-12-3102337313bus:FRS1022024-01-012024-12-3102337313bus:Audited2024-01-012024-12-3102337313bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP